Simulations Plus

The company has produced specific proprietary software products, such as: • GastroPlus™, a physiologically-based simulation tool that predicts the absorption, pharmacokinetics, pharmacodynamics, and drug-drug interactions for compounds administered through intravenous, oral, ocular, or pulmonary routes. • ADMET Predictor™, an ADME-Tox property prediction and model building application. • MedChem Studio™, a multi-purpose cheminformatics platform used for advanced data mining and de novo molecule design. • DDDPlus™, a simulation program for formulation scientists that predicts the in vitro disintegration and dissolution of solid dosage forms under different experimental conditions. • MedChem Designer™, a FREE chemical sketching product that combines innovative molecule drawing features with fast and accurate ADMET property predictions from ADMET Predictor. As of January 2014, 19 of the top 20 pharmaceutical companies, along with most major regulatory agencies, license the company's software.
Company Growth (employees)
Type
Public
HQ
Lancaster, US
Founded
1996
Size (employees)
60 (est)+6%
Simulations Plus was founded in 1996 and is headquartered in Lancaster, US

Simulations Plus Office Locations

Simulations Plus has offices in Lancaster and Buffalo
Lancaster, US (HQ)
42505 10th St W
Buffalo, US
110 1780 Wehrle Dr

Simulations Plus Metrics

Simulations Plus Financial Metrics

Simulations Plus's revenue was reported to be $20 m in 2016 which is a 9% increase from the previous period.

Revenue (Y, 2016)

$20 m

Revenue growth (Y, 2015 - Y, 2016), %

9%

Gross profit (Y, 2016)

$15.4 m

Gross profit margin (Y, 2016), %

77%

Net income (Y, 2016)

$5 m

EBIT (Y, 2016)

$7.2 m

Market capitalization (19-May-2017)

$199.1 m

Closing share price (19-May-2017)

$11.5

Cash (31-Aug-2016)

$8 m
Simulations Plus's current market capitalization is $199.1 m.
Y, 2014Y, 2015Y, 2016

Revenue

$11.5 m$18.3 m$20 m

Revenue growth, %

60%9%

Cost of goods sold

$1.6 m$4.3 m$4.6 m

Gross profit

$9.8 m$14 m$15.4 m

Gross profit Margin, %

86%76%77%

Operating expense total

$5.4 m$8.1 m$8.1 m

EBIT

$4.4 m$5.9 m$7.2 m

EBIT margin, %

39%32%36%

Interest income

$31.4 k$17.9 k$18 k

Pre tax profit

$4.5 m

Income tax expense

($1.5 m)($1.8 m)($2.3 m)

Net Income

$3 m$3.8 m$5 m
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$8.6 m$8.6 m$8 m

Accounts Receivable

Inventories

$188.2 k$381.7 k$410.8 k

Current Assets

$11.5 m$11.5 m$12.9 m

PP&E

$95.2 k$413.5 k$256.4 k

Goodwill

$4.8 m$4.8 m

Total Assets

$21 m$27.3 m$28 m

Accounts Payable

$130.5 k$209.4 k$108.1 k

Current Liabilities

$1.4 m$3.6 m$2.1 m

Additional Paid-in Capital

$6.1 m$9.7 m$11.4 m

Retained Earnings

$9.3 m$9.8 m$11.3 m

Total Equity

$15.4 m$19.5 m$22.7 m

Financial Leverage

1.4 x1.4 x1.2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$3 m$3.8 m$5 m

Accounts Receivable

$1 m($1.4 m)

Inventories

$192.2 k

Accounts Payable

$146 k($15.5 k)$19.4 k($101.3 k)

Cash From Operating Activities

$5.3 m$7.1 m$5.4 m

Purchases of PP&E

($24.5 k)($71.4 k)($39.1 k)

Cash From Investing Activities

($3.9 m)($3.1 m)($2 m)

Interest Paid

Income Taxes Paid

$692.6 k$961.9 k$2.9 m
Y, 2016

Revenue/Employee

$350.4 k

Financial Leverage

1.2 x

Simulations Plus Market Value History

Simulations Plus Online Presence

Simulations Plus Company Life

You may also be interested in